Summary: The BioFreedom Drug Coated Coronary Stent System is a polymer-free stent designed for patients at high risk of bleeding. It is primarily used to improve coronary luminal diameter in symptomatic ischemic heart disease. Key evidence highlights its efficacy and safety in high bleeding risk patients.
The BioFreedom Drug Coated Coronary Stent System received FDA premarket approval (PMA) on April 14, 2022. It is manufactured by Biosensors International U and classified as a Class III device.
What It Is
The BioFreedom Drug Coated Coronary Stent System is a polymer-free, drug-coated stent designed to improve coronary luminal diameter in patients with symptomatic ischemic heart disease. It is intended for use in de novo lesions in native coronary arteries, particularly in patients at high risk for bleeding.
Clinical Applications
This device is commonly used in patients with symptomatic ischemic heart disease who are at high risk for bleeding. It is suitable for treating de novo lesions of up to 32 mm in length in native coronary arteries with diameters ranging from 2.25 mm to 4.0 mm.
Evidence Summary
The available literature includes 15 studies, comprising randomized controlled trials, prospective and retrospective studies, and case series, published between 2020 and 2023. These studies evaluate the safety and efficacy of the BioFreedom stent in various clinical scenarios.
Reported Outcomes
Published studies report that the BioFreedom stent is effective in improving coronary luminal diameter and reducing restenosis rates in patients at high bleeding risk. The device has shown noninferiority to other modern stents in terms of clinical outcomes, with some studies highlighting its superiority over bare-metal stents.
Safety Profile
Reported complications include bleeding events, although these are generally lower compared to other stent types due to the polymer-free design. The studies indicate a favorable safety profile, particularly in high bleeding risk patients.
Evidence Limitations
The evidence is limited by the relatively short follow-up periods and the specific focus on high bleeding risk populations. Further research is needed to evaluate long-term outcomes and to compare the BioFreedom stent with other contemporary stent technologies in broader patient populations.
Frequently Asked Questions
What are the clinical indications for BioFreedom Drug Coated Coronary Stent System?
The device is indicated for improving coronary luminal diameter in patients at high risk for bleeding with symptomatic ischemic heart disease due to de novo lesions in native coronary arteries.
What outcomes have been reported in clinical studies?
Clinical studies have reported improved coronary luminal diameter and reduced restenosis rates, with some studies showing noninferiority to modern stents and superiority over bare-metal stents.
What complications have been reported?
Reported complications include bleeding events, but these are generally lower compared to other stent types due to the polymer-free design, indicating a favorable safety profile.
Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference.
It does not constitute medical advice, product endorsement, or a recommendation for clinical use.
Always consult manufacturer documentation and clinical judgment for patient care decisions.
📬 Stay Updated
Get the latest vascular education content delivered to your inbox.